Orphines: The Synthetic Opioid Class No Test Strip Can Detect

Orphines are derived from a benzimidazol-2-one scaffold — a fused bicyclic ring system consisting of a benzene ring joined to an imidazolinone ring. This core structure is fundamentally different from both the piperidine-phenethyl scaffold of fentanyl and the benzimidazole scaffold of nitazenes. The most prominent orphine identified in the US drug supply is cychlorphine (also written as "chlorphine" in some reports). Cychlorphine was originally synthesized in a Russian pharmaceutical research program and patented in the 1970s but was never brought to clinical use. It acts as a full agonist at the mu-opioid receptor with an estimated potency approximately 10 times that of fentanyl. Other orphines detected or anticipated include borphine, phorphine, and several uncharacterized analogs with varying substitution patterns on the benzimidazolone ring. The structural diversity possible within this class is similar to what was seen with fentanyl analogs — once the core scaffold is established, illicit chemists can generate dozens of variants by modifying side chains and substituents.

The emergence of orphines follows a pattern that has repeated across synthetic opioid classes. When a drug class is scheduled or its precursors are restricted, manufacturers shift to alternative scaffolds. Fentanyl analogs surged after heroin precursor controls tightened in the 2010s. Nitazenes appeared as fentanyl precursor chemicals came under international scrutiny. In early 2025, China implemented new regulations targeting nitazene precursors, placing several key starting materials under export controls. Within months, orphines began appearing in seized drug samples and overdose cases in the United States. The supply chain adapted. The structural distance between orphines and previously scheduled compounds is not accidental — it is a deliberate strategy to avoid both law enforcement detection and the immunoassay-based rapid testing infrastructure that has been built around fentanyl detection.

As of early 2026, orphines have been identified in drug samples or overdose death investigations in at least 12 US states. The initial concentration was in the eastern United States, with East Tennessee emerging as a particular hotspot. The Tennessee Bureau of Investigation and the Knox County Regional Forensic Center reported 19 death investigations involving cychlorphine in a six-month period spanning late 2025 and early 2026 — a rate that, if sustained, would make orphines a leading contributor to overdose deaths in that region. The Center for Forensic Science Research and Education (CFSRE) issued its first technical alert on orphines in mid-2025, and subsequent alerts have tracked the geographic spread. Orphines have also been detected in samples analyzed by the DEA\'s Special Testing and Research Laboratory and by several state public health laboratory networks. The pattern of geographic spread is consistent with what was observed with nitazenes: initial detection in a handful of eastern states, followed by westward expansion over 12-18 months as supply chains mature.

Immunoassay-based rapid test strips work by antibody recognition of molecular structure. The antibodies in fentanyl test strips — whether single-antibody or broad-spectrum cocktail formulations — are designed to recognize structural features of the fentanyl molecular family (the piperidine ring, the phenethyl group, the acyl chain) or the nitazene family (the benzimidazole core with its nitro group). Orphines share none of these features. The benzimidazol-2-one scaffold of orphines has no meaningful structural overlap with either fentanyl or nitazene class compounds. Antibodies generated against fentanyl or nitazene haptens have no reason to bind orphines, and there is no published evidence of cross-reactivity. Developing a rapid immunoassay for orphines would require generating new antibodies against an orphine hapten — a process that takes 12-18 months from hapten design through antibody production, screening, conjugation, and lateral flow strip validation. Even then, the same cat-and-mouse dynamic would apply: as orphine analogs proliferate with structural modifications, an orphine-specific antibody panel would face the same detection gap challenges that fentanyl strips faced with fentanyl analogs.

Orphines are mu-opioid receptor agonists, which means naloxone can reverse their effects. This is a critical distinction from xylazine, which is not an opioid and does not respond to naloxone. However, the estimated potency of cychlorphine (approximately 10 times fentanyl) may require higher naloxone doses or repeated administration to achieve reversal. This is similar to the naloxone dosing challenges seen with carfentanil and some nitazenes. Programs distributing naloxone should brief their staff and participants on the possibility of encountering orphines and the potential need for additional naloxone doses. Standard guidance of "administer a second dose if no response after 2-3 minutes" remains appropriate, but responders should be prepared to administer a third dose if available and to call 911 immediately, as high-potency opioid reversal may require sustained naloxone infusion that only emergency medical services can provide.

The emergence of orphines does not make fentanyl testing obsolete — fentanyl remains the dominant synthetic opioid in the US drug supply and will continue to be for the foreseeable future. But orphines represent a detection gap that users and programs need to know about. Concrete steps for harm reduction programs: (1) Brief staff on orphines — what they are, that test strips cannot detect them, and that naloxone still works but may require higher doses. (2) Co-distribute naloxone with every FTS distribution. The case for co-distribution is stronger than ever when undetectable opioids are in circulation. (3) Monitor CFSRE alerts and your state forensic lab\'s drug trend reports for orphine detections in your service area. (4) Communicate honestly with participants: "Your fentanyl test strip checks for fentanyl and fentanyl-related compounds. There are new synthetic opioids it cannot detect. Always use with naloxone nearby and never use alone." (5) Advocate for expanded drug checking: mass spectrometry and FTIR spectroscopy can identify orphines, and some drug checking services are already adding them to reference libraries. (6) Support funding for orphine-specific rapid test development through public health channels and research partnerships.